

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5949699/publications.pdf>

Version: 2024-02-01

357
papers

70,244
citations

1094

112
h-index

621

258
g-index

366
all docs

366
docs citations

366
times ranked

61196
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA signatures in human cancers. <i>Nature Reviews Cancer</i> , 2006, 6, 857-866.	12.8	7,008
2	A microRNA expression signature of human solid tumors defines cancer gene targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2257-2261.	3.3	5,220
3	MicroRNA Gene Expression Deregulation in Human Breast Cancer. <i>Cancer Research</i> , 2005, 65, 7065-7070.	0.4	3,719
4	MicroRNAs in Cancer. <i>Annual Review of Medicine</i> , 2009, 60, 167-179.	5.0	1,702
5	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 15805-15810.	3.3	1,538
6	MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 425-36.	3.8	1,386
7	MicroRNA Signatures in Human Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 8699-8707.	0.4	1,356
8	Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. <i>Cancer Cell</i> , 2014, 26, 707-721.	7.7	1,293
9	MicroRNAs in body fluids—the mix of hormones and biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 467-477.	12.5	1,290
10	miRNAs, Cancer, and Stem Cell Division. <i>Cell</i> , 2005, 122, 6-7.	13.5	1,271
11	MicroRNAs and other non-coding RNAs as targets for anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 847-865.	21.5	1,234
12	The role of microRNA genes in papillary thyroid carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 19075-19080.	3.3	1,137
13	A MicroRNA Signature of Hypoxia. <i>Molecular and Cellular Biology</i> , 2007, 27, 1859-1867.	1.1	990
14	A microRNA DNA methylation signature for human cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13556-13561.	3.3	990
15	Clinical relevance of circulating cell-free microRNAs in cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 145-156.	12.5	915
16	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2007, 67, 6092-6099.	0.4	782
17	Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. <i>Lancet Oncology</i> , The, 2010, 11, 136-146.	5.1	752
18	Noncoding RNA therapeutics — challenges and potential solutions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 629-651.	21.5	749

#	ARTICLE	IF	CITATIONS
19	MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5166-5171.	3.3	741
20	MicroRNAs – the micro steering wheel of tumour metastases. Nature Reviews Cancer, 2009, 9, 293-302.	12.8	740
21	RNA interference in the clinic: challenges and future directions. Nature Reviews Cancer, 2011, 11, 59-67.	12.8	729
22	MicroRNA expression and function in cancer. Trends in Molecular Medicine, 2006, 12, 580-587.	3.5	699
23	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	7.7	681
24	Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer. Cancer Research, 2008, 68, 6162-6170.	0.4	661
25	Long Noncoding RNA in Prostate, Bladder, and Kidney Cancer. European Urology, 2014, 65, 1140-1151.	0.9	601
26	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 2008, 111, 3183-3189.	0.6	575
27	Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by miR-29 and miR-181. Cancer Research, 2006, 66, 11590-11593.	0.4	568
28	Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 387-392.	0.8	566
29	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 2016, 6, 235-246.	7.7	554
30	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
31	miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. Cell, 2010, 140, 652-665.	13.5	514
32	PDL1 Regulation by p53 via miR-34. Journal of the National Cancer Institute, 2016, 108, .	3.0	475
33	CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2750-2755.	3.3	473
34	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	0.6	463
35	Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression. Cancer Cell, 2008, 13, 496-506.	7.7	459
36	MicroRNAome genome: A treasure for cancer diagnosis and therapy. Ca-A Cancer Journal for Clinicians, 2014, 64, 311-336.	157.7	428

#	ARTICLE	IF	CITATIONS
37	MicroRNA 29b functions in acute myeloid leukemia. <i>Blood</i> , 2009, 114, 5331-5341.	0.6	412
38	The multiMiR R package and database: integration of microRNA target interactions along with their disease and drug associations. <i>Nucleic Acids Research</i> , 2014, 42, e133-e133.	6.5	409
39	MicroRNA fingerprints during human megakaryocytopoiesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5078-5083.	3.3	403
40	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5060-5072.	3.2	386
41	Data Normalization Strategies for MicroRNA Quantification. <i>Clinical Chemistry</i> , 2015, 61, 1333-1342.	1.5	384
42	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1106-15.	3.3	376
43	Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility. <i>Cancer Research</i> , 2010, 70, 2789-2798.	0.4	365
44	Tumour angiogenesis regulation by the miR-200 family. <i>Nature Communications</i> , 2013, 4, 2427.	5.8	363
45	microRNA Therapeutics in Cancer – An Emerging Concept. <i>EBioMedicine</i> , 2016, 12, 34-42.	2.7	360
46	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. <i>Nature Genetics</i> , 2009, 41, 365-370.	9.4	355
47	Clinical utility of circulating non-coding RNAs – an update. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 541-563.	12.5	353
48	MicroRNA history: Discovery, recent applications, and next frontiers. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 717, 1-8.	0.4	351
49	Regulation of Tumor Angiogenesis by EZH2. <i>Cancer Cell</i> , 2010, 18, 185-197.	7.7	346
50	Reprogramming of miRNA networks in cancer and leukemia. <i>Genome Research</i> , 2010, 20, 589-599.	2.4	331
51	MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. <i>Molecular Aspects of Medicine</i> , 2019, 70, 3-20.	2.7	307
52	A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of Cancer Cells. <i>Cancer Cell</i> , 2010, 18, 303-315.	7.7	299
53	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	298
54	MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. <i>PLoS ONE</i> , 2009, 4, e7405.	1.1	273

#	ARTICLE	IF	CITATIONS
55	Cell-cell communication: microRNAs as hormones. <i>Molecular Oncology</i> , 2017, 11, 1673-1686.	2.1	267
56	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. <i>Cancer</i> , 2012, 118, 2603-2614.	2.0	265
57	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 59.	3.8	256
58	An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210. <i>Journal of Biological Chemistry</i> , 2009, 284, 35134-35143.	1.6	248
59	The Potential of MicroRNAs as Prostate Cancer Biomarkers. <i>European Urology</i> , 2016, 70, 312-322.	0.9	243
60	Loss of p53 drives neuron reprogramming in head and neck cancer. <i>Nature</i> , 2020, 578, 449-454.	13.7	241
61	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. <i>Molecular Cancer</i> , 2007, 6, 54.	7.9	240
62	MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 9090-9095.	0.4	229
63	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA <i>PCA3</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8403-8408.	3.3	226
64	SnapShot: MicroRNAs in Cancer. <i>Cell</i> , 2009, 137, 586-586.e1.	13.5	223
65	miR-124 Inhibits STAT3 Signaling to Enhance T Cell-Mediated Immune Clearance of Glioma. <i>Cancer Research</i> , 2013, 73, 3913-3926.	0.4	223
66	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4394-4399.	3.3	222
67	MicroRNAs and cancer—new paradigms in molecular oncology. <i>Current Opinion in Cell Biology</i> , 2009, 21, 470-479.	2.6	219
68	RNAi Therapies: Drugging the Undruggable. <i>Science Translational Medicine</i> , 2014, 6, 240ps7.	5.8	215
69	Low frequency of alterations of the $\hat{1}^{\pm}$ (PPP2R1A) and $\hat{1}^2$ (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. <i>Oncogene</i> , 2000, 19, 1191-1195.	2.6	206
70	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. <i>Nature Cell Biology</i> , 2015, 17, 311-321.	4.6	205
71	Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. <i>Journal of Cellular Physiology</i> , 2007, 210, 370-377.	2.0	203
72	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. <i>Blood</i> , 2010, 116, 945-952.	0.6	200

#	ARTICLE	IF	CITATIONS
73	The fusion of two worlds: Non-coding RNAs and extracellular vesicles - diagnostic and therapeutic implications (Review). <i>International Journal of Oncology</i> , 2015, 46, 17-27.	1.4	192
74	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 1207-1214.	3.2	191
75	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 1891-1899.	0.6	184
76	MicroRNAs and cancer: Profile, profile, profile. <i>International Journal of Cancer</i> , 2008, 122, 969-977.	2.3	182
77	Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. <i>Gastroenterology</i> , 2012, 142, 886-896.e9.	0.6	174
78	Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer. <i>Molecular Therapy</i> , 2014, 22, 1494-1503.	3.7	172
79	MicroRNAs. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 1-6.	1.0	171
80	<i>CCAT2</i> , a novel long non-coding RNA in breast cancer: expression study and clinical correlations. <i>Oncotarget</i> , 2013, 4, 1748-1762.	0.8	169
81	Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. <i>Cancer Research</i> , 2017, 77, 5808-5819.	0.4	169
82	Progresses towards safe and efficient gene therapy vectors. <i>Oncotarget</i> , 2015, 6, 30675-30703.	0.8	163
83	MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 546-554.	0.6	162
84	MIR-138 exerts anti-glioma efficacy by targeting immune checkpoints. <i>Neuro-Oncology</i> , 2016, 18, 639-648.	0.6	161
85	Epigenetics and miRNAs in Human Cancer. <i>Advances in Genetics</i> , 2010, 70, 87-99.	0.8	160
86	Targeting microRNAs as key modulators of tumor immune response. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 103.	3.5	160
87	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. <i>EBioMedicine</i> , 2018, 38, 100-112.	2.7	159
88	Prooncogenic Factors miR-23b and miR-27b Are Regulated by Her2/Neu, EGF, and TNF- α in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 2884-2896.	0.4	158
89	Cell-to-cell miRNA transfer: From body homeostasis to therapy. , 2012, 136, 169-174.		156
90	miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. <i>Molecular Oncology</i> , 2014, 8, 83-92.	2.1	156

#	ARTICLE	IF	CITATIONS
91	Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. <i>EMBO Journal</i> , 2013, 32, 2672-2684.	3.5	152
92	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	13.5	152
93	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , 2014, 5, 5202.	5.8	151
94	Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. <i>Journal of Clinical Investigation</i> , 2007, 117, 2059-2066.	3.9	151
95	Regulatory mechanisms of microRNAs involvement in cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1009-1019.	1.4	150
96	MicroRNA profiling in cancer. <i>Clinical Science</i> , 2011, 121, 141-158.	1.8	150
97	MicroRNA Processing and Human Cancer. <i>Journal of Clinical Medicine</i> , 2015, 4, 1651-1667.	1.0	150
98	Exosomal lncRNAs as new players in cell-to-cell communication. <i>Translational Cancer Research</i> , 2018, 7, S243-S252.	0.4	150
99	Small molecule compounds targeting miRNAs for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2015, 81, 104-116.	6.6	142
100	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. <i>Molecular Cell</i> , 2016, 61, 520-534.	4.5	142
101	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. <i>Cancer Discovery</i> , 2013, 3, 1302-1315.	7.7	140
102	MicroRNA genes are frequently located near mouse cancer susceptibility loci. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8017-8022.	3.3	138
103	Regulation of pri-miRNA Processing by a Long Noncoding RNA Transcribed from an Ultraconserved Region. <i>Molecular Cell</i> , 2014, 55, 138-147.	4.5	137
104	Cancer Hallmarks and MicroRNAs: The Therapeutic Connection. <i>Advances in Cancer Research</i> , 2017, 135, 119-149.	1.9	135
105	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015, 6, 37269-37280.	0.8	135
106	Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. <i>Prostate</i> , 2008, 68, 1152-1164.	1.2	134
107	Regulation of microRNA Expression: the Hypoxic Component. <i>Cell Cycle</i> , 2007, 6, 1425-1430.	1.3	132
108	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. <i>Blood</i> , 2009, 113, 5568-5574.	0.6	129

#	ARTICLE	IF	CITATIONS
109	Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. <i>Epigenetics</i> , 2010, 5, 656-663.	1.3	125
110	RNAi-based therapeutics and tumor targeted delivery in cancer. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114113.	6.6	123
111	miRNAs and long noncoding RNAs as biomarkers in human diseases. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 183-204.	1.5	122
112	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	3.2	122
113	A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. <i>EMBO Journal</i> , 2013, 32, 2833-2847.	3.5	120
114	The Clinical Relevance of Long Non-Coding RNAs in Cancer. <i>Cancers</i> , 2015, 7, 2169-2182.	1.7	120
115	Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. <i>Cancer Research</i> , 2016, 76, 7194-7207.	0.4	118
116	Circular RNAs in Cancer – Lessons Learned From microRNAs. <i>Frontiers in Oncology</i> , 2018, 8, 179.	1.3	115
117	Targeting non-coding RNAs to overcome cancer therapy resistance. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 121.	7.1	114
118	Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	112
119	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. <i>Gut</i> , 2016, 65, 977-989.	6.1	111
120	An miR-502 Binding Site Single-Nucleotide Polymorphism in the 3' Untranslated Region of the <i>SET8</i> Gene Is Associated with Early Age of Breast Cancer Onset. <i>Clinical Cancer Research</i> , 2009, 15, 6292-6300.	3.2	106
121	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8- β -Catenin Signaling in Colorectal Cancer. <i>EBioMedicine</i> , 2016, 13, 113-124.	2.7	106
122	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015, 13, 2395-2402.	2.9	105
123	Role of miRNAs in immune responses and immunotherapy in cancer. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 244-253.	1.5	105
124	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. <i>Scientific Reports</i> , 2013, 3, 2687.	1.6	104
125	HypoxamiRs and Cancer: From Biology to Targeted Therapy. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 1220-1238.	2.5	102
126	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. <i>Blood</i> , 2011, 118, 413-415.	0.6	101

#	ARTICLE	IF	CITATIONS
127	Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein. <i>Nutrition and Cancer</i> , 2016, 68, 154-164.	0.9	101
128	Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. <i>Blood</i> , 2009, 114, 4761-4770.	0.6	100
129	Molecular Pathways: microRNAs, Cancer Cells, and Microenvironment. <i>Clinical Cancer Research</i> , 2014, 20, 6247-6253.	3.2	99
130	Noncoding <scp>RNA</scp>s and immune checkpointsâ€™ clinical implications as cancer therapeutics. <i>FEBS Journal</i> , 2017, 284, 1952-1966.	2.2	99
131	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. <i>Genome Biology</i> , 2017, 18, 98.	3.8	97
132	The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors. <i>Frontiers in Immunology</i> , 2019, 10, 1053.	2.2	95
133	Classical and noncanonical functions of miRNAs in cancers. <i>Trends in Genetics</i> , 2022, 38, 379-394.	2.9	94
134	Decrypting noncoding RNA interactions, structures, and functional networks. <i>Genome Research</i> , 2019, 29, 1377-1388.	2.4	93
135	Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2013, 8, e73009.	1.1	93
136	MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. <i>Genome Medicine</i> , 2011, 3, 56.	3.6	92
137	MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. <i>Hepatology</i> , 2011, 54, 2089-2098.	3.6	91
138	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e83113.	1.1	91
139	Clinically Relevant microRNAs in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 393-401.	1.5	90
140	RNA-Binding Proteins as Important Regulators of Long Non-Coding RNAs in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2969.	1.8	89
141	The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 425-437.	0.7	87
142	Non-coding RNAs regulation of macrophage polarization in cancer. <i>Molecular Cancer</i> , 2021, 20, 24.	7.9	86
143	Regulation of microRNA expression: the hypoxic component. <i>Cell Cycle</i> , 2007, 6, 1426-31.	1.3	86
144	Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. <i>Blood</i> , 2009, 113, 3744-3753.	0.6	85

#	ARTICLE	IF	CITATIONS
145	The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. <i>Cancer Microenvironment</i> , 2010, 3, 137-147.	3.1	85
146	Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. <i>Cancer Research</i> , 2021, 81, 1431-1440.	0.4	84
147	Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. <i>Oncogene</i> , 2015, 34, 1619-1628.	2.6	82
148	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. <i>Oncotarget</i> , 2017, 8, 11641-11658.	0.8	81
149	MicroRNA based theranostics for brain cancer: basic principles. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 231.	3.5	81
150	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. <i>Cellular Signalling</i> , 2020, 68, 109539.	1.7	81
151	<scp>MicroRNAs</scp> as therapeutic targets in human cancers. <i>Wiley Interdisciplinary Reviews RNA</i> , 2014, 5, 537-548.	3.2	80
152	Epigenetic Regulation of miRNAs in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 137-148.	0.8	79
153	Cross Talk Between MicroRNA and Coding Cancer Genes. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 223-231.	1.0	77
154	Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 473.	1.8	77
155	Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. <i>Non-coding RNA</i> , 2015, 1, 53-68.	1.3	76
156	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. <i>Cell Reports</i> , 2016, 15, 1493-1504.	2.9	75
157	Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. <i>Molecular Carcinogenesis</i> , 2018, 57, 137-141.	1.3	75
158	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , 2020, 159, 2146-2162.e33.	0.6	75
159	MicroRNAs: Fundamental facts and involvement in human diseases. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2006, 78, 180-189.	3.6	74
160	A miRNA signature associated with human metastatic medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2013, 20, 809-823.	1.6	74
161	Using microRNA Networks to Understand Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1871.	1.8	74
162	Examining plasma microRNA markers for colorectal cancer at different stages. <i>Oncotarget</i> , 2016, 7, 11434-11449.	0.8	74

#	ARTICLE	IF	CITATIONS
163	Functional relevance of miRNA* sequences in human disease. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2012, 731, 14-19.	0.4	72
164	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw026.	3.0	70
165	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. <i>Carcinogenesis</i> , 2010, 31, 208-215.	1.3	68
166	Non-coding RNAs: Identification of Cancer-Associated microRNAs by Gene Profiling. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 123-138.	0.8	67
167	Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3982-3991.	3.2	67
168	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NF κ B pathway. <i>Molecular Cancer</i> , 2013, 12, 173.	7.9	66
169	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. <i>Oncotarget</i> , 2016, 7, 20636-20654.	0.8	66
170	Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. <i>Mammalian Genome</i> , 2008, 19, 526-40.	1.0	65
171	Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-Stable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7283-7293.	3.2	65
172	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. <i>Clinical Cancer Research</i> , 2018, 24, 4225-4241.	3.2	64
173	MicroRNAs in the ontogeny of leukemias and lymphomas. <i>Leukemia and Lymphoma</i> , 2009, 50, 160-170.	0.6	63
174	Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. <i>Molecular Cancer</i> , 2013, 12, 13.	7.9	63
175	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e270.	2.3	63
176	MiR-181 family-specific behavior in different cancers: a meta-analysis view. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 17-32.	2.7	63
177	Current Status of Long Non-Coding RNAs in Human Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1485.	1.8	62
178	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. <i>Nature Communications</i> , 2018, 9, 461.	5.8	61
179	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 15093-15104.	0.8	61
180	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2127-2137.	3.2	60

#	ARTICLE	IF	CITATIONS
181	Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 593-605.	1.1	60
182	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e41170.	1.1	59
183	Non-coding RNAs: the cancer genome dark matter that matters!. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 705-714.	1.4	58
184	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutations. <i>Genome Research</i> , 2018, 28, 432-447.	2.4	58
185	NCRNA Combined Therapy as Future Treatment Option for Cancer. <i>Current Pharmaceutical Design</i> , 2014, 20, 6565-6574.	0.9	58
186	MicroRNAs, Regulatory Messengers Inside and Outside Cancer Cells. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1056, 87-108.	0.8	57
187	Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. <i>Molecular Cancer</i> , 2013, 12, 50.	7.9	56
188	Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. <i>Oncotarget</i> , 2017, 8, 20145-20164.	0.8	56
189	MALAT1 promoted invasiveness of gastric adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 46.	1.1	54
190	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. <i>Endocrine-Related Cancer</i> , 2010, 17, F51-F75.	1.6	53
191	Non-coding RNAs as theranostics in human cancers. <i>Journal of Cellular Biochemistry</i> , 2011, 113, n/a-n/a.	1.2	52
192	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. <i>Clinical Cancer Research</i> , 2014, 20, 4141-4153.	3.2	52
193	MicroRNAs and ceRNAs: therapeutic implications of RNA networks. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1285-1293.	1.4	52
194	Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 193-214.	1.5	52
195	MicroRNAs and Cancer Therapy – From Bystanders to Major Players. <i>Current Medicinal Chemistry</i> , 2013, 20, 3561-3573.	1.2	50
196	Key principles of miRNA involvement in human diseases. <i>Discoveries</i> , 2014, 2, e34.	1.5	50
197	miR-195 inhibits macrophages pro-inflammatory profile and impacts the crosstalk with smooth muscle cells. <i>PLoS ONE</i> , 2017, 12, e0188530.	1.1	49
198	MiR-200 family and cancer: From a meta-analysis view. <i>Molecular Aspects of Medicine</i> , 2019, 70, 57-71.	2.7	49

#	ARTICLE	IF	CITATIONS
199	The ZNF304-integrin axis protects against anoikis in cancer. <i>Nature Communications</i> , 2015, 6, 7351.	5.8	48
200	To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2003.	1.8	48
201	A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 50.	1.8	48
202	Non-coding RNAs and ferroptosis: potential implications for cancer therapy. <i>Cell Death and Differentiation</i> , 2022, 29, 1094-1106.	5.0	48
203	From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. <i>Frontiers in Oncology</i> , 2015, 5, 21.	1.3	47
204	MicroRNAs, ultraconserved genes and colorectal cancers. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1291-1297.	1.2	46
205	Novel Insights of Structure-Based Modeling for RNA-Targeted Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 2741-2753.	2.5	46
206	The Mix of Two Worlds: Non-Coding RNAs and Hormones. <i>Nucleic Acid Therapeutics</i> , 2013, 23, 2-8.	2.0	45
207	The Many Faces of Long Noncoding RNAs in Cancer. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 922-935.	2.5	45
208	Over-expression of the <i>miR-483-3p</i> overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 31361-31371.	0.8	45
209	Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. <i>Oncotarget</i> , 2013, 4, 1388-1398.	0.8	44
210	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. <i>EBioMedicine</i> , 2015, 2, 572-582.	2.7	43
211	Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF- κ B Activation and Enhances Erythroid Differentiation Arrest. <i>PLoS ONE</i> , 2014, 9, e93404.	1.1	42
212	MicroRNAs and Ultraconserved Genes as Diagnostic Markers and Therapeutic Targets in Cancer and Cardiovascular Diseases. <i>Journal of Cardiovascular Translational Research</i> , 2010, 3, 271-279.	1.1	41
213	MicroRNAs in cancer therapeutics: "from the bench to the bedside". <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1381-1385.	1.4	40
214	MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. <i>Cancers</i> , 2020, 12, 2009.	1.7	40
215	Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3770-3775.	3.3	39
216	Ultraconserved long non-coding RNA uc.63 in breast cancer. <i>Oncotarget</i> , 2017, 8, 35669-35680.	0.8	38

#	ARTICLE	IF	CITATIONS
217	The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 449-455.	3.3	37
218	MicroRNAs and Long Non-Coding RNAs and Their Hormone-Like Activities in Cancer. <i>Cancers</i> , 2019, 11, 378.	1.7	37
219	Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 53165-53177.	0.8	37
220	Non-coding RNAs and cancer: new paradigms in oncology. <i>Discovery Medicine</i> , 2011, 11, 245-54.	0.5	37
221	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1667-1683.	1.4	36
222	Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. <i>Cell Discovery</i> , 2017, 3, 17029.	3.1	36
223	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. <i>Nature Communications</i> , 2017, 8, 1801.	5.8	36
224	Key questions about the checkpoint blockade-are microRNAs an answer?. <i>Cancer Biology and Medicine</i> , 2018, 15, 103.	1.4	36
225	Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1580.	1.7	36
226	Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer. <i>Cells</i> , 2019, 8, 1638.	1.8	36
227	Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 5642-5654.	2.0	35
228	Long Non-coding RNAs in Myeloid Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1048.	1.3	35
229	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. <i>Oncotarget</i> , 2015, 6, 7262-7279.	0.8	35
230	MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities. <i>Current Pathobiology Reports</i> , 2013, 1, 43-52.	1.6	34
231	FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs. <i>Non-coding RNA</i> , 2020, 6, 41.	1.3	34
232	GAM/ZFP/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGF β 2 effectors, Drosha and microRNAs with opposite oncogenic potentials. <i>Nucleic Acids Research</i> , 2010, 38, 7673-7688.	6.5	32
233	A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. <i>Genome Medicine</i> , 2014, 6, 76.	3.6	32
234	The protein phosphatase 2A regulatory subunit B55 β is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 1969-1977.	1.9	32

#	ARTICLE	IF	CITATIONS
235	MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. <i>Carcinogenesis</i> , 2009, 30, 912-917.	1.3	31
236	Signal Transducer and Activator of Transcription α 3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e64678.	1.1	31
237	MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?. <i>Seminars in Oncology</i> , 2016, 43, 209-214.	0.8	31
238	Metformin blocks <i>MYC</i> protein synthesis in colorectal cancer via <i>mTOR</i> and <i>EBP</i> and <i>MNK1</i> signaling. <i>Molecular Oncology</i> , 2018, 12, 1856-1870.	2.1	31
239	Editing and Chemical Modifications on Non-Coding RNAs in Cancer: A New Tale with Clinical Significance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 581.	1.8	31
240	Circulating miRNAs in sepsis: A network under attack: An in-silico prediction of the potential existence of miRNA sponges in sepsis. <i>PLoS ONE</i> , 2017, 12, e0183334.	1.1	31
241	RNA Inhibition, MicroRNAs, and New Therapeutic Agents for Cancer Treatment. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S313-S318.	1.4	30
242	MicroRNAs: Toward the Clinic for Breast Cancer Patients. <i>Seminars in Oncology</i> , 2011, 38, 764-775.	0.8	30
243	Circulating microRNAs as Promising Tumor Biomarkers. <i>Advances in Clinical Chemistry</i> , 2014, 67, 189-214.	1.8	30
244	Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?. <i>Frontiers in Medicine</i> , 2015, 2, 85.	1.2	30
245	Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. <i>Seminars in Cancer Biology</i> , 2019, 58, 47-55.	4.3	30
246	Clinical significance of the interaction between non-coding RNAs and the epigenetics machinery. <i>Epigenetics</i> , 2014, 9, 75-80.	1.3	29
247	Understanding the Genomic Ultraconservations: T-UCRs and Cancer. <i>International Review of Cell and Molecular Biology</i> , 2017, 333, 159-172.	1.6	29
248	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 340-345.	2.9	29
249	Principles of microRNA involvement in human cancers. <i>Chinese Journal of Cancer</i> , 2011, 30, 739-748.	4.9	29
250	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. <i>Modern Pathology</i> , 2015, 28, 373-382.	2.9	28
251	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. <i>Clinical Cancer Research</i> , 2016, 22, 2359-2367.	3.2	28
252	Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex. <i>EMBO Reports</i> , 2020, 21, e46734.	2.0	28

#	ARTICLE	IF	CITATIONS
253	A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. <i>Nature Biomedical Engineering</i> , 2021, 5, 297-308.	11.6	28
254	Non-coding RNAs for Medical Practice in Oncology. <i>Keio Journal of Medicine</i> , 2011, 60, 106-113.	0.5	27
255	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. <i>Cancers</i> , 2020, 12, 2148.	1.7	27
256	MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44. <i>Scientific Reports</i> , 2021, 11, 9219.	1.6	26
257	Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. <i>Haematologica</i> , 2018, 103, 2069-2078.	1.7	25
258	Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs. <i>Seminars in Cancer Biology</i> , 2022, 83, 197-207.	4.3	25
259	miRNA as Potential Biomarkers of Breast Cancer in the Lebanese Population and in Young Women: A Pilot Study. <i>PLoS ONE</i> , 2014, 9, e107566.	1.1	25
260	The role of exosomal long non-coding RNAs in cancer drug resistance. , 2019, 2, 1178-1192.		25
261	Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. <i>International Journal of Oncology</i> , 2011, 38, 1153-61.	1.4	24
262	Hematopoietic stem cells from induced pluripotent stem cells " considering the role of microRNA as a cell differentiation regulator. <i>Journal of Cell Science</i> , 2018, 131, .	1.2	24
263	The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 301-317.	2.3	24
264	Therapeutic Potential of the miRNA-ATM Axis in the Management of Tumor Radioresistance. <i>Cancer Research</i> , 2020, 80, 139-150.	0.4	24
265	OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. <i>Scientific Reports</i> , 2018, 8, 13106.	1.6	23
266	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. <i>Clinical Epigenetics</i> , 2019, 11, 71.	1.8	23
267	microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis. <i>Scientific Reports</i> , 2017, 7, 16829.	1.6	22
268	Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk. <i>Cancer Letters</i> , 2018, 421, 94-102.	3.2	22
269	Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. <i>RNA Biology</i> , 2020, 17, 1523-1534.	1.5	22
270	Circulating Non-coding RNAs in Renal Cell Carcinoma's Pathogenesis and Potential Implications as Clinical Biomarkers. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 828.	1.8	22

#	ARTICLE	IF	CITATIONS
271	Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma. <i>Molecular and Cellular Probes</i> , 2015, 29, 420-426.	0.9	21
272	miR-122 and hepatocellular carcinoma: from molecular biology to therapeutics. <i>EBioMedicine</i> , 2018, 37, 17-18.	2.7	21
273	Long non-coding RNA CCAT2 as a therapeutic target in colorectal cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 973-976.	1.5	20
274	The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , 2019, 104, 1004-1015.	1.7	20
275	The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3387.	1.8	20
276	microRNA-10b: A New Marker or the Marker of Pancreatic Ductal Adenocarcinoma?. <i>Clinical Cancer Research</i> , 2011, 17, 5527-5529.	3.2	19
277	MicroRNAs as Main Players in the Pathogenesis of Chronic Lymphocytic Leukemia. <i>MicroRNA (Shariqah)</i> , Tj ETQq1 1 0.784314 rgBT /Qv 0.6 19	0.6	19
278	Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. <i>EBioMedicine</i> , 2017, 20, 182-192.	2.7	19
279	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 194.	1.8	18
280	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. <i>JCI Insight</i> , 2020, 5, .	2.3	18
281	Patients After Splenectomy: Old Risks and New Perspectives. <i>Chirurgia (Romania)</i> , 2016, 111, 393.	0.2	18
282	Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 335-352.	1.5	17
283	The non-coding RNome after splenectomy. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7844-7858.	1.6	17
284	Highlighting transcribed ultraconserved regions in human diseases. <i>Wiley Interdisciplinary Reviews RNA</i> , 2020, 11, e1567.	3.2	17
285	Epigenetically regulated microRNAs and their prospect in cancer diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 673-683.	1.5	16
286	A Multiscale Agent-Based Model of Ductal Carcinoma <i>In Situ</i> . <i>IEEE Transactions on Biomedical Engineering</i> , 2020, 67, 1450-1461.	2.5	16
287	targetHub: a programmable interface for miRNA-gene interactions. <i>Bioinformatics</i> , 2013, 29, 2657-2658.	1.8	14
288	From mobility to crosstalk. A model of intracellular miRNAs motion may explain the RNAs interaction mechanism on the basis of target subcellular localization. <i>Mathematical Biosciences</i> , 2016, 280, 50-61.	0.9	14

#	ARTICLE	IF	CITATIONS
289	Expression profiles of micro RNA in proliferating and differentiating 32D murine myeloid cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 706-710.	2.0	13
290	microRNA and Chronic Lymphocytic Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 2015, 889, 23-40.	0.8	12
291	Non-Coding RNAs as Cancer Hallmarks in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6720.	1.8	12
292	Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. <i>British Journal of Haematology</i> , 2020, 190, 249-261.	1.2	12
293	Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue. <i>Cancers</i> , 2021, 13, 681.	1.7	12
294	Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. <i>Pharmaceutical Research</i> , 2022, 39, 511-528.	1.7	12
295	MicroRNAs: Clinical Trials and Potential Applications. <i>Clinical Journal of Oncology Nursing</i> , 2017, 21, 554-559.	0.3	11
296	Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. <i>Clinical Epigenetics</i> , 2020, 12, 150.	1.8	11
297	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. <i>Cancer Cell International</i> , 2020, 20, 403.	1.8	11
298	Fractal-like kinetics of intracellular enzymatic reactions: a chemical framework of endotoxin tolerance and a possible non-specific contribution of macromolecular crowding to cross-tolerance. <i>Theoretical Biology and Medical Modelling</i> , 2013, 10, 55.	2.1	10
299	SnapShot: Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2014, 26, 770-770.e1.	7.7	10
300	Interrupting Neuron-Tumor Interactions to Overcome Treatment Resistance. <i>Cancers</i> , 2020, 12, 3741.	1.7	10
301	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3529.	1.0	10
302	Crucial role of non-coding RNAs in disease. <i>Cancer Letters</i> , 2018, 420, 127-128.	3.2	9
303	Profiling the circulating miRnome reveals a temporal regulation of the bone injury response. <i>Theranostics</i> , 2018, 8, 3902-3917.	4.6	9
304	When non-coding is not enough. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	9
305	Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis megalin in acute myeloid leukaemia: Therapeutic implications. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7378-7392.	1.6	9
306	MicroRNAs in Myeloid Hematological Malignancies. <i>Current Genomics</i> , 2015, 16, 336-348.	0.7	9

#	ARTICLE	IF	CITATIONS
307	Analysis of the circRNA and T-UCR populations identifies convergent pathways in mouse and human models of Rett syndrome. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 621-644.	2.3	9
308	EGFR gets in the way of microRNA biogenesis. <i>Cell Research</i> , 2013, 23, 1157-1158.	5.7	7
309	Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. <i>Oncolimmunology</i> , 2016, 5, e1117739.	2.1	7
310	The noncoding <sc>RNA</sc> revolutionâ€™three decades and still going strong!. <i>Molecular Oncology</i> , 2019, 13, 3-3.	2.1	7
311	MicroRNAs in Leukemias: A Clinically Annotated Compendium. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3469.	1.8	7
312	Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. <i>Methods in Molecular Biology</i> , 2016, 1402, 33-41.	0.4	6
313	Allele Frequencies of Variants in Ultra Conserved Elements Identify Selective Pressure on Transcription Factor Binding. <i>PLoS ONE</i> , 2014, 9, e110692.	1.1	6
314	Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19. <i>Cancers</i> , 2021, 13, 5220.	1.7	6
315	Small gene, big number, many effects. <i>Blood</i> , 2012, 120, 240-241.	0.6	5
316	Welcome to the New Journal Non-Coding RNA!. <i>Non-coding RNA</i> , 2015, 1, 1-3.	1.3	5
317	When kissing (disease) counts. <i>Blood</i> , 2016, 127, 1947-1948.	0.6	5
318	From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks. <i>Oncolimmunology</i> , 2016, 5, e1230579.	2.1	5
319	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 266-277.	3.0	5
320	Viral Micro-RNAs Are Detected in the Early Systemic Response to Injury and Are Associated With Outcomes in Polytrauma Patients. <i>Critical Care Medicine</i> , 2022, 50, 296-306.	0.4	5
321	Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
322	MiR-sensing chemotherapy resistance in CLL. <i>Blood</i> , 2009, 113, 3652-3653.	0.6	3
323	The Role of MicroRNAs and Ultraconserved Non-Coding RNAs in Cancer. , 2014, , 435-447.		3
324	The interplay between lncRNAs, SNPs, and protein complexes - what does it mean for cancer metabolism?. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1166308.	0.3	3

#	ARTICLE	IF	CITATIONS
325	miRNA Expression Assays. , 2019, , 51-71.		3
326	Pyknon-Containing Transcripts Are Downregulated in Colorectal Cancer Tumors, and Loss of PYK44 Is Associated With Worse Patient Outcome. <i>Frontiers in Genetics</i> , 2020, 11, 581454.	1.1	3
327	How Does a Tumor Get Its Shape? MicroRNAs Act as Morphogens at the Cancer Invasion Front. <i>Non-coding RNA</i> , 2020, 6, 23.	1.3	3
328	Molecular aspects of medicine – Editorial 2019. <i>Molecular Aspects of Medicine</i> , 2019, 70, 1-2.	2.7	2
329	Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 682129.	1.3	2
330	MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2016, 5, 106-112.	0.6	2
331	Pseudogenes, RNAs and new reproducibility norms. <i>ELife</i> , 2020, 9, .	2.8	2
332	lncRNAs UC.145 and PRKG1-AS1 Determine the Functional Output of DKK1 in Regulating the Wnt Signaling Pathway in Gastric Cancer. <i>Cancers</i> , 2022, 14, 2369.	1.7	2
333	Principles of MicroRNA Involvement in Breast Cancer. <i>Breast Diseases</i> , 2011, 22, 238-243.	0.0	1
334	Beyond miRNAs: Role of Other Noncoding RNAs in Cancer. , 2014, , 247-264.		1
335	Drug – MicroRNA Cross-Talk. , 2015, , 991-1016.		1
336	MiRNA Expression Assays. , 2015, , 45-70.		1
337	Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	1
338	Measurement of miRNAs in Chronic Lymphocytic Leukemia Patient Samples by Quantitative Reverse Transcription PCR. <i>Methods in Molecular Biology</i> , 2019, 1881, 267-276.	0.4	1
339	Preface for GCC Special Issue on noncoding RNAs, noncoding DNAs, and genome editing. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 189-190.	1.5	1
340	TNF-alpha releasing capacity of the whole blood drops after open total splenectomy, but increases after partial/subtotal or minimally invasive splenectomy. <i>Acta Chirurgica Belgica</i> , 2022, 122, 346-356.	0.2	1
341	JAM-ming miR-21. <i>Cell Death and Differentiation</i> , 2021, 28, 2837-2839.	5.0	1
342	MicroRNAs as Therapeutic Targets. , 2015, , 683-697.		1

#	ARTICLE	IF	CITATIONS
343	CpG island hypermethylation go circular (RNA). <i>Oncotarget</i> , 2018, 9, 33052-33053.	0.8	1
344	microRNA in cancer: An overview. , 2022, , 21-28.		1
345	MicroRNAs and Other Non-Coding RNAs: Implications for Cancer Patients. , 2013, , 1-12.		0
346	Small silencing non-coding RNAs: cancer connections and significance. , 0, , 481-496.		0
347	Therapeutic Potential of microRNAs. , 2015, , 543-564.		0
348	Estrogen and breast cancer: can less mean more?. <i>Cell Cycle</i> , 2015, 14, 2197-2198.	1.3	0
349	MicroRNA Involvement in Intestinal Tumorigenesis. , 2015, , 169-188.		0
350	The Non-Coding RNA Journal Club: Highlights on Recent Papersâ€™6. <i>Non-coding RNA</i> , 2018, 4, 23.	1.3	0
351	New Insights into the Molecular Mechanisms of Long Non-coding RNAs in Cancer Biology. , 2019, , 85-113.		0
352	Profiling Long Non-coding RNA expression Using Custom-Designed Microarray. <i>Methods in Molecular Biology</i> , 2021, 2372, 43-51.	0.4	0
353	Effects of long non-coding RNAs on androgen signaling pathways in genitourinary malignancies. <i>Molecular and Cellular Endocrinology</i> , 2021, 526, 111197.	1.6	0
354	Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis. , 2018, , 11-25.		0
355	Diagnostic and Therapeutic MicroRNAs in Primary Myelofibrosis. <i>Proceedings of the Singapore National Academy of Science</i> , 2020, 14, 91-109.	0.1	0
356	Tumorigenesis-Related Long Noncoding RNAs and Their Targeting as Therapeutic Approach in Cancer. <i>RNA Technologies</i> , 2020, , 277-303.	0.2	0
357	RNA delivery for cancer gene therapy. , 2022, , 375-424.		0